| "Type 2 diabetes mellitus is characterised by resistance of peripheral tissues to insulin and a relative deficiency of insulin secretion." | ( Bergman, RN; Kahn, CR; Krolewski, AS; Martin, BC; Soeldner, JS; Warram, JH, 1992) |
| "Type 1 and type 2 diabetes mellitus are both characterized by increased cardiovascular mortality and morbidity." | ( Giberti, B; Micossi, P; Parlavecchia, M; Ruotolo, G; Zoppo, A, 1991) |
| "Type 2 diabetes mellitus is associated with an exaggerated glucose dependent insulinotropic polypeptide response to oral glucose and mixed meals which is independent of any effect of obesity." | ( Hayes, TM; Jones, IR; Luzio, S; Owens, DR; Williams, S, 1989) |
| "Type 2 diabetes mellitus is a dynamic disease whose natural history is characterized by a progressive aggravation leading to a progressively severe hyperglycaemia, which generally requires a more complex therapy as time progresses." | ( Lefèbvre, PJ; Paquot, N; Scheen, AJ, 1999) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action." | ( DeFronzo, RA, 1999) |
| "Type 2 diabetes mellitus is one of the most common chronic metabolic diseases in man." | ( Ferreira, FM; Palmeira, CM; Santos, MS; Seiça, R, 1999) |
| "Type 2 diabetes mellitus is a progressive disorder, and although oral monotherapy is often initially successful, it is associated with a high secondary failure rate, which contributes to the development of long-term diabetes complications resulting from persistent hyperglycemia." | ( Riddle, M, 2000) |
| "Type 2 diabetes mellitus is characterized by impaired glucose uptake." | ( Cheng, WY; Feng, HF; Hu, XJ; Peng, F; Zhang, ZH; Zhou, HQ, 2000) |
| "Type 2 diabetes mellitus is characterised by abnormal beta-cell function (present at the time of diagnosis) that is often associated with insulin resistance." | ( Lauritzen, T; Nattrass, M, 2000) |
| "Type 2 diabetes mellitus is a growing problem not only in the United States but also across the world." | ( Henry, RR; Mudaliar, S, 2001) |
| "Type 2 diabetes mellitus is a complex heterogenous metabolic disorder in which peripheral insulin resistance and impaired insulin release are the main pathogenetic factors." | ( Landgraf, R, 2000) |
| "Type 2 diabetes mellitus is a common metabolic disorder that has become a major public health problem because of the long-term microvascular and macrovascular complications associated with it." | ( Kumar, S; Valsamakis, G, 2000) |
| "Type 2 diabetes mellitus is characterised by impaired insulin secretion, diminished peripheral insulin action and increased hepatic glucose production." | ( Huijberts, MS; Sels, JP; Wolffenbuttel, BH, 2001) |
| "Type 2 diabetes mellitus is characterized by insulin deficiency but in particular by insulin resistance." | ( Rybka, J, 2001) |
| "Type 2 diabetes mellitus is associated with accelerated atherosclerosis and a high rate of arterial thrombotic complications." | ( Badimon, JJ; Crandall, JP; Fallon, JT; Fuster, V; Heflt, G; Herson, P; Lev, EI; Osende, JI; Rabito, P; Rauch, U; Rodriguez, OJ; Vidhun, R; Zaman, A, 2001) |
| "Type 2 diabetes mellitus is characterized by insulin-resistant glucose and lipid metabolism." | ( Davis, AO; Klein, S; McGill, JB; Racette, SB, 2002) |
| "Hyperglycemia and type 2 diabetes mellitus are more common in schizophrenia than in the general population." | ( Cooper, BP; Fucetola, R; Haupt, DW; Melson, AK; Newcomer, JW; Schweiger, JA; Selke, G, 2002) |
| "Type 2 diabetes mellitus is a common disease whose complications have great costs, both in quality of life and expense of treatment." | ( Caro, J; Salas, M; Ward, A, 2002) |
| "Type 2 diabetes mellitus is a social and civilization-related disease that leads to various micro- and macroangiopathic complications, including diabetic nephropathy." | ( Bartłomiejczyk, I; Kropiewnicka, HE; Paczek, L; Senatorski, G, 2002) |
| "Type 2 diabetes mellitus is associated with a heavy burden of suffering." | ( Donahue, K; Frame, P; Harris, R; Lohr, KN; Rathore, SS; Woolf, SH, 2003) |
| "Type 2 diabetes mellitus is characterized by both insulin deficiency and insulin resistance." | ( Bokhari, SU; Duckworth, WC; Gopal, UM, 2003) |
| "Type 2 diabetes mellitus is frequently accompanied by hypercoagulability and hypofibrinolysis." | ( Brussaard, HE; Kluft, C; Krans, HM; Leuven, JA, 2002) |
| "Type 2 diabetes mellitus is the commonest form of diabetes." | ( Ramachandran, A, 2002) |
| "Type 2 diabetes mellitus is an increasingly prevalent disorder associated with multiple metabolic derangements." | ( Basu, A; Kudva, YC; Zangeneh, F, 2003) |
| "Type 2 diabetes mellitus is a major health problem associated with excess morbidity and mortality." | ( Scheen, AJ, 2003) |
| "Type 2 diabetes mellitus is characterised both by impaired release of insulin and by resistance to the action of insulin." | ( Pørksen, N, 2002) |
| "Type 2 diabetes mellitus is characterised by insulin resistance as well as progressive pancreatic beta cell dysfunction." | ( Diamant, M; Heine, RJ, 2003) |
| "The prevalence of type 2 diabetes mellitus is increasing in children and adolescents worldwide, particularly among minority youth." | ( Homko, CJ; Reece, EA, 2003) |
| "Patients with type 2 diabetes mellitus are associated with insulin resistance and/or impaired insulin secretion." | ( Odawara, M, 2003) |
| "Patients with type 2 diabetes mellitus are at an increased risk of atherosclerosis including peripheral arterial disease (PAD)." | ( Emoto, M; Kimoto, E; Koyama, H; Nishizawa, Y; Shinohara, K; Shoji, T; Tanaka, S; Yokoyama, H, 2003) |
| "Patients with type 2 diabetes mellitus are at increased risk for postangioplasty restenosis, which results from excessive intimal hyperplasia." | ( Bruemmer, D; Law, RE, 2003) |
| "Type 2 diabetes mellitus is a major health problem associated with excess morbidity and mortality." | ( Schernthaner, G, 2003) |
| "The risk of type 2 diabetes mellitus is increased in people who have low birth weights and who subsequently become obese as adults." | ( Barker, DJ; Bhargava, SK; Biswas, SK; Fall, CH; Lakshmy, R; Osmond, C; Prabhakaran, D; Ramji, S; Reddy, KS; Sachdev, HS, 2004) |
| "Type 2 diabetes mellitus is the consequence of both insulin resistance and impaired insulin secretion." | ( Abrahamson, MJ, 2004) |
| "Type 2 diabetes mellitus is the most common serious metabolic condition in the world, and results from a subnormal response of tissues to insulin (insulin resistance) and a failure of the insulin-secreting beta cells to compensate." | ( Klover, PJ; Mooney, RA, 2004) |
| "Type 2 diabetes mellitus is associated with impaired endothelial function and increased levels of TNF-alpha, IL-6 and sVCAM-1, especially in patients with DM and CAD." | ( Antoniades, C; Stefanadis, C; Tentolouris, C; Tountas, C; Tousoulis, D; Toutouza, M; Toutouzas, P; Tsioufis, C; Vasiliadou, C, 2004) |
| "Type 2 diabetes mellitus is a condition characterized by impaired insulin secretion and resistance to insulin-mediated glucose uptake and utilization." | ( Bates, PC; Dietrich, K; Lübben, G; Seufert, J, 2004) |
| "The management of type 2 diabetes mellitus is complicated by the presence of risk factors related to overweight and obesity, particularly visceral adiposity." | ( Berber, A; Campos-Franco, E; Fanghänel, G; Martínez-Rivas, L; Sánchez-Reyes, L; Yamamoto, J, 2004) |
| "Type 2 diabetes mellitus is associated with an augmented risk for cardiovascular disease." | ( Alcaraz Tafalla, MS; Carrillo Alcaraz, A; Illán Gómez, F; Pascual Díaz, M, 2004) |
| "Type 2 diabetes mellitus is a growing epidemic." | ( Anderson, DC, 2005) |
| "Type 2 diabetes mellitus is a common problem in patients after solid organ transplantation." | ( Baldwin, D; Luther, P, 2004) |
| "Type 2 diabetes mellitus is a progressive and complex disorder that is difficult to treat effectively in the long term." | ( Bailey, CJ; Krentz, AJ, 2005) |
| "Rates of type 2 diabetes mellitus are increasing worldwide at an explosive rate." | ( Leiter, LA; Lewanczuk, RZ, 2005) |
| "Patients with type 2 diabetes mellitus are at high risk of cardiovascular disease." | ( Forst, T; Füllert, SD; Hohberg, C; Kann, P; Konrad, T; Langenfeld, MR; Lübben, G; Pfützner, A; Sachara, C, 2005) |
| "Type 2 diabetes mellitus is a widespread disease, affecting millions of people globally." | ( Barbetti, F; Brunetti, A; Brunetti, L; Chiefari, E; Croce, CM; Fedele, M; Foti, D; Fusco, A; Iuliano, R; Manfioletti, G; Paonessa, F, 2005) |
| "Type 2 diabetes mellitus is a disease with a high incidence and prevalence in the world." | ( Arredondo, M; Leiva, E; Mujica, V; Orrego, R; Prieto, M, 2005) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action." | ( Giorgino, F; Laviola, L; Leonardini, A, 2005) |
| "Type 2 diabetes mellitus is increasing globally and is an established risk factor for the development of atherosclerotic vascular disease." | ( Channer, KS; Jones, TH; Kapoor, D; Malkin, CJ, 2005) |
| "Type 2 diabetes mellitus is a heterogeneous condition in which the clinical manifestation of hyperglycemia is a reflection of the impaired balance between insulin sensitivity and insulin secretion." | ( Arslanian, S; Bacha, F; Gungor, N; Hannon, T; Libman, I, 2005) |
| "Type 2 diabetes mellitus is a chronic disease with potentially devastating long-term complications." | ( Jacobson-Dickman, E; Levitsky, L, 2005) |
| "The prevalence of type 2 diabetes mellitus is rapidly increasing." | ( Dounis, V; Hansen, A; Malmberg, K; Rydén, L; Thrainsdottir, IS; Von Bibra, H, 2005) |
| "Patients with type 2 diabetes mellitus are at increased risk of cardiovascular disease, partly owing to dyslipidaemia, which can be amenable to fibrate therapy." | ( Barter, P; Best, J; Colman, P; d'Emden, M; Davis, T; Drury, P; Ehnholm, C; Forder, P; Glasziou, P; Hunt, D; Keech, A; Kesäniemi, YA; Laakso, M; Pillai, A; Scott, R; Simes, RJ; Sullivan, D; Taskinen, MR; Whiting, M, 2005) |
| "The prevalence of type 2 diabetes mellitus is increasing rapidly in industrialized countries, and adrenal glucocorticoids may intensify this disease." | ( Born, J; Dodt, B; Fehm, HL; Oltmanns, KM; Peters, A; Raspe, HH; Schultes, B; Schweiger, U, 2006) |
| "Type 2 diabetes mellitus is a major cause of morbidity and mortality worldwide, and the prevalence is set to increase dramatically over the coming decades." | ( Petersen, KF; Shulman, GI, 2006) |
| "Type 2 diabetes mellitus is increasing to near epidemic proportions, with a reported 190 million patients worldwide." | ( Sawyer, TS; Spiller, HA, 2006) |
| "Type 2 diabetes mellitus is a multigenic disease with evident genetic predisposition, and complex pathogenesis in which environmental and genetic factors interact." | ( Chang, YS; Fang, FD; He, AB; Liu, XJ, 2006) |
| "Type 2 diabetes mellitus is associated with abnormal MBF response to CPT, which can be significantly improved by euglycaemic control with glyburide and metformin." | ( Cadenas, J; Facta, AD; Hsueh, WA; Prior, JO; Quinones, MJ; Schelbert, HR; Schindler, TH, 2007) |
| "Type 2 diabetes mellitus is a cause of primary NAFLD." | ( Chung, CH; Leung, CH; Liu, SC; Wang, CH, 2006) |
| "Type 2 diabetes mellitus is usually preceded by impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG), which are often referred to as pre-diabetes." | ( Schwartz, S, 2006) |
| "Type 2 diabetes mellitus is the single most common cause of chronic kidney disease (CKD); however its real impact on renal anaemia has not been established." | ( Andreucci, M; Faga, T; Francesco, M; Fuiano, G; Li Vecchi, M; Mancuso, D; Provenzano, R; Sponton, A; Tozzo, C, 2007) |
| "Type 2 diabetes mellitus is the result of a combination of impaired insulin secretion with reduced insulin sensitivity of target tissues." | ( Bentley, E; Cheeseman, M; Connor, SC; Cox, RD; Griffin, JL; Haselden, JN; Hough, T; Maguire, ML; Nunez, D; Rubtsov, DV; Salek, RM; Sweatman, BC, 2007) |
| "Most patients with type 2 diabetes mellitus are overweight or obese, and the relation between obesity, especially of the visceral compartment, and the risk for developing diabetes is well recognized." | ( Aronne, LJ; Lee, M, 2007) |
| "Type 2 diabetes mellitus is a strong predictor of cerebrovascular disease, yet few studies have assessed the incidence of stroke and the role of other risk factors in unselected type 2 diabetes mellitus populations." | ( Alegiani, SS; Avogaro, A; Ferrannini, E; Giorda, CB; Lombardo, F; Maggini, M; Mannucci, E; Raschetti, R; Turco, S; Velussi, M, 2007) |
| "Patients with type 2 diabetes mellitus are at increased risk for macrovascular disease complications." | ( McGuire, DK; Stancoven, A, 2007) |
| "Type 2 diabetes mellitus is twice as prevalent in African Americans and Hispanic Americans as in non-Hispanic whites." | ( Cobitz, AR; Davidson, JA; McMorn, SO; Waterhouse, BR, 2007) |
| "Type 2 diabetes mellitus is associated with elevated plasma triglyceride levels, low high-density lipoprotein cholesterol, and a high incidence of cardiovascular disease." | ( Bergeron, J; Couture, P; Gagné, C; Hogue, JC; Lamarche, B; Tremblay, AJ, 2008) |
| "Type 2 diabetes mellitus is associated with progressive decreases in pancreatic beta-cell function." | ( Gutkin, SW; Nauck, MA; Van Gaal, LF, 2008) |
| "Type 2 diabetes mellitus is a common age-dependent disease." | ( Cheon, GJ; Cho, KA; Ha, MK; Jun, HS; Khil, LY; Lee, TS; Oh, YS; Park, SC; Ryu, SJ; Yoon, JW, 2008) |
| "Type 2 diabetes mellitus is usually accompanied by concomitant disorders, such as dyslipidemia, hypertension and atherosclerosis." | ( Elisaf, MS; Liberopoulos, EN; Mikhailidis, DP; Rizos, CV, 2008) |
| "Type 2 diabetes mellitus is associated with elevated level of oxidative stress, which is one of the most important factors responsible for the development of chronic complications of this disease." | ( Blasiak, J; Drzewoski, J; Kasznicki, J; Sliwinska, A, 2008) |
| "Patients with type 2 diabetes mellitus are at increased risk for the development of atherosclerosis." | ( Ayers, CR; Hedrick, CC; Mauldin, JP; McNamara, CA; Nagelin, MH; Skaflen, MD; Srinivasan, S; Wojcik, AJ, 2008) |
| "A review of Type 2 diabetes mellitus is presented." | ( Hall, MA, 2008) |
| "Type 2 diabetes mellitus is characterized by insulin resistance, impaired glucose-induced insulin secretion, and inappropriately elevated glucagon levels which eventually result in hyperglycemia." | ( Knop, FK; Vilsbøll, T, 2008) |
| "Type 2 diabetes mellitus is a worldwide health problem." | ( Sriwijitkamol, A; Thongtang, N, 2008) |
| "Type 2 diabetes mellitus is a complex disease characterized by beta-cell failure in the setting of insulin resistance." | ( Bernal-Mizrachi, E; Chang-Chen, KJ; Mullur, R, 2008) |
| "New treatments for type 2 diabetes mellitus are needed to retain insulin-glucose coupling and lower the risk of weight gain and hypoglycaemia." | ( Bode, B; Garber, A; Garcia-Hernandez, PA; Hale, PM; Henry, R; Olvera-Alvarez, I; Ratner, R; Rodriguez-Pattzi, H; Zdravkovic, M, 2009) |
| "Type 2 diabetes mellitus is associated with an increased risk of cardiovascular diseases and accelerated atherosclerosis, which has been associated to hyperglycemia and chronic inflammation." | ( Bernard, EA; de Souza, LF; de Souza, MM; Jardim, FR; Sauter, IP, 2008) |
| "Type 2 diabetes mellitus is a metabolic disease leading to microvascular and macrovascular complications including coronary artery disease and stroke." | ( Fonseca, VA; John-Kalarickal, J; Wani, JH, 2008) |
| "Type 2 diabetes mellitus is associated with a marked increase in the risk of coronary heart disease (CHD) or stroke (by a factor of two to three compared with non-diabetic patients), and cardiovascular disease (CVD) accounts for the majority of deaths among patients with diabetes." | ( Balasubramanian, R; Baliga, VP; Bolmall, C; Kathale, A; Nagraj, LM; Nayak, UP; Periyandavar, I; Sharma, A; Varadharajan, S, 2008) |
| "Type 2 diabetes mellitus is an increasingly prevalent condition worldwide." | ( Feinglos, M; Green, J, 2008) |
| "Type 2 diabetes mellitus is the leading cause of macrovascular diseases and related death." | ( Erem, C; Ersoz, HO; Hacihasanoglu, AB; Karti, SS; Ukinc, K, 2009) |
| "Type 2 diabetes mellitus is a growing public health concern throughout the world." | ( Conway, JR; MacNair, D; Marble, RJ; Patasi, B, 2009) |
| "Type 2 diabetes mellitus is a multifactorial metabolic disorder." | ( Fonseca, VA; John-Kalarickal, J; Surampudi, PN, 2009) |
| "Type 2 diabetes mellitus is a major and increasingly prevalent independent risk factor for cardiovascular morbidity and mortality worldwide." | ( Gore, MO; McGuire, DK, 2009) |
| "Type 2 diabetes mellitus is a progressive disease characterized by persistent insulin resistance and a relentless decline in insulin secretion that is accelerated by chronic hyperglycemia." | ( Rosenstock, J, 2004) |
| "Type 2 diabetes mellitus is associated with high mortality and morbidity, mainly due to coronary artery disease and atherosclerosis, although female gender is a protective factor in the development of, for example, atherosclerosis and hypertension." | ( Kamata, K; Kobayashi, T; Matsumoto, T; Taguchi, K; Takenouchi, Y, 2009) |
| "Type 2 diabetes mellitus is a complex metabolic disease that is caused by insulin resistance and beta-cell dysfunction." | ( Fritsche, A; Häring, HU; Machicao, F; Staiger, H, 2009) |
| "Type 2 diabetes mellitus is a common, chronic and progressive metabolic disorder, which accounts for 90% of diabetes cases worldwide." | ( Casellini, CM; Fernández Landó, L, 2009) |
| "Type 2 diabetes mellitus is a disease characterized by persistent and progressive deterioration of glucose tolerance." | ( Del Prato, S, 2009) |
| "Type 2 diabetes mellitus is associated with low high-density lipoprotein (HDL) cholesterol levels, which is an independent cardiovascular risk factor." | ( Schultheiss, HP; Spillmann, F; Tschöpe, C; Van Linthout, S, 2010) |
| "Type 2 diabetes mellitus is a chronic debilitating disease characterized by insulin resistance and progressive pancreatic dysfunction." | ( Henry, RR; Mudaliar, S, 2010) |
| "Type 2 diabetes mellitus is a complicated metabolic disease affecting millions of individuals worldwide." | ( Parkin, CG; Unger, J, 2010) |
| "The increase in type 2 diabetes mellitus is associated to cardiovascular morbidity and mortality." | ( Ghiadoni, L, 2010) |
| "Type 2 diabetes mellitus is associated with increased risk of malignancy (mainly cancer of the pancreas, breast, colon, endometrium and bladder)." | ( Maltezos, E; Mikhailidis, DP; Papanas, N, 2010) |
| "Patients with type 2 diabetes mellitus are characterized by increased incidence of cardiovascular events and enhanced thromboxane-dependent platelet activation." | ( Davì, G; Mucci, L; Santilli, F, 2011) |
| "T2D (Type 2 diabetes mellitus) is a major health issue that has reached epidemic status worldwide." | ( Bushell, M; Ferland-McCollough, D; Ozanne, SE; Siddle, K; Willis, AE, 2010) |
| "Type 2 diabetes mellitus is a well-established risk factor for cardiovascular disease (CVD)." | ( Adamidou, F; Anagnostis, P; Athyros, VG; Karagiannis, A; Kita, M; Mikhailidis, DP; Panagiotou, A, 2011) |
| "Type 2 diabetes mellitus is increasing in prevalence at alarming rates." | ( Giorgino, F; Laviola, L; Leonardini, A; Natalicchio, A, 2011) |
| "Type 2 diabetes mellitus is an independent risk factor for the development of cardiovascular disease." | ( Alvarez de Sotomayor, M; Herrera, MD; Justo, ML; Mingorance, C; Rodríguez-Rodríguez, R, 2011) |
| "Type 2 diabetes mellitus is a complex metabolic disease and its pathogenesis involves abnormalities in both peripheral insulin action and insulin secretion by pancreatic beta cells." | ( Benito, M, 2011) |
| "The incidence of type 2 diabetes mellitus is increasing worldwide." | ( Chawla, S; Ghosh, RK; Ghosh, SM; Jasdanwala, SA, 2012) |
| "Type 2 diabetes mellitus is one of the significant comorbidities of obesity." | ( Eid, WE, 2011) |
| "It was studied that type 2 diabetes mellitus is connected with increased plasma lipid peroxidation (lipid peroxidation expressed as malondialdehyde)." | ( Marjani, A, 2010) |
| "Type 2 diabetes mellitus is characterised by beta cell failure, which frequently develops in the setting of insulin resistance." | ( Drucker, DJ; Rosen, CF, 2011) |
| "Type 2 diabetes mellitus is associated with a 2- to 4-fold increased risk of coronary heart disease (CHD)." | ( Arora, R; Dey, S; Kandhwal, K; Monif, T; Nazarudheen, S; Rao, S; Reyar, S; Singh, MK; Thudi, NR, 2011) |
| "Type 2 diabetes mellitus is a growing problem in pediatrics and there is no consensus on the best treatment." | ( Hoffman, RP; Meyer, SL, 2011) |
| "Type 2 diabetes mellitus is associated with a progressive decline in insulin-producing pancreatic β-cells, an increase in hepatic glucose production, and a decrease in insulin sensitivity." | ( Holst, JJ; McGill, MA, 2012) |
| "Type 2 diabetes mellitus is frequently accompanied by fatty liver/nonalcoholic fatty liver disease." | ( Ishii, S; Ohta, T; Sakai, K; Shiraishi, M; Tsuchida, T, 2012) |
| "Type 2 diabetes mellitus is likely the third modifiable risk factor for pancreatic cancer after cigarette smoking and obesity." | ( Li, D, 2012) |
| "Type 2 diabetes mellitus is thought to be a significant risk factor for Alzheimer's disease." | ( Kasahara, R; Matsubara, T; Naruse, K; Sato, T; Sobue, K; Suzuki, K; Tanida, M; Taniura, H; Yamamoto, N, 2012) |
| "Type 2 diabetes mellitus is a progressive disease characterized by multiple abnormalities that extend beyond β-cell dysfunction and insulin resistance." | ( Freeman, JS, 2012) |
| "The prevalence of type 2 diabetes mellitus is high among the elderly population." | ( Marrs, JC, 2012) |
| "Type 2 diabetes mellitus is a multisystem disease that is characterized by hyperglycemia and is associated with the dysfunction and failure of various organs." | ( Kim, KJ; Lee, BY; Yoon, KY, 2012) |
| "Type 2 diabetes mellitus is the main cause of chronic kidney disease in developed countries." | ( Ardiles A, L; Parra L, X; Villarroel R, P, 2012) |
| "Type 2 diabetes mellitus is a major global public health problem in the worldwide and is increasing in aging populations." | ( Cheng, FC; Huang, JH; Lee, JN; Lu, YF; Tsai, LC, 2012) |
| "Type 2 diabetes mellitus is increasing over time as result of the obesity epidemics." | ( Castagneto-Gissey, L; Mingrone, G, 2012) |
| "Patients with type 2 diabetes mellitus are at 2 to 4 times increased risk of cardiovascular events compared with those without diabetes, both among patients with multiple risk factors only and those with established atherothrombosis." | ( Bhatt, DL; Braunwald, E; Davidson, J; Hirshberg, B; Raz, I; Scirica, BM; Steg, PG; Udell, JA, 2012) |
| "Type 2 diabetes mellitus is associated with a higher risk of hepatocellular carcinoma (HCC), which is attenuated by the use of metformin." | ( Chang, CC; Chen, HP; Chen, TT; Lin, JH; Lin, JT; Shieh, JJ; Wu, CY; Wu, MS, 2013) |
| "Type 2 diabetes mellitus is characterized by insulin resistance with a relative deficiency in insulin secretion." | ( Bouzakri, K; Halban, PA; Plomgaard, P, 2012) |
| "Type 2 diabetes mellitus is associated with risk of congestive heart failure (CHF), cognitive dysfunction and depression." | ( Deary, IJ; Feinkohl, I; Price, JF; Reynolds, RM; Sattar, N; Strachan, MW; Welsh, P, 2012) |
| "Type 2 diabetes mellitus is associated with an increased blood thrombogenicity among NSTE-ACS patients on currently recommended medical therapy." | ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Schechter, CB; Viswanathan, GN; Zaman, AG, 2012) |
| "Type 2 diabetes mellitus is characterized by insulin resistance and progressive β cell failure; therefore, β cell secretagogues are useful for achieving sufficient glycemic control." | ( Basit, A; Fawwad, A; Riaz, M, 2012) |
| "Patients with type 2 diabetes mellitus are routinely treated with combinations of glucose-lowering agents." | ( Boardman, MK; Haber, H; Liutkus, JF; Norwood, P; Pintilei, E; Trautmann, ME, 2012) |
| "Type 2 diabetes mellitus is a multifactorial and polygenic disease, which is considered as a major life threatening problem all over the world." | ( Abbas, S; Ahmed, F; Fatima, J; Mahdi, F; Raza, ST; Zaidi, ZH, 2012) |
| "Type 2 diabetes mellitus is a chronic dysmetabolic condition characterized by hyperglycemia and accompanied by dyslipidemia (low HDL, high triglycerides), and hypertension associated with insulin resistance in obesity." | ( de Galan, BE; Simsek, S, 2012) |
| "Type 2 diabetes mellitus is associated with reduced incretin effects." | ( Chan, JC; Deng, Y; Fan, RR; Kang, ZF; Laybutt, DR; Luzuriaga, J; Xu, G; Zhou, Y, 2013) |
| "Type 2 diabetes mellitus is widely prevalent and is often coexistent with obesity." | ( Davies, MJ; Kela, R; Khunti, K; Nisal, K, 2012) |
| "Type 2 diabetes mellitus is a progressive disease characterized by an impairment of insulin action, and failure of pancreatic β-cells to compensate for the enhanced insulin demand." | ( Sesti, G, 2012) |
| "Type 2 diabetes mellitus is characterized by hyperglycaemia." | ( Hak, L; Wolnik, B, 2013) |
| "Type 2 diabetes mellitus is a metabolic noncommunicable disease with an expanding pandemic magnitude." | ( Berlanga-Acosta, J; García-Siverio, M; Guillen-Nieto, G; Herrera-Martínez, L; López-Mola, E; Schultz, GS, 2013) |
| "Type 2 diabetes mellitus is a rising cause of cardiovascular morbidity and mortality." | ( Elisaf, MS; Rizos, CV, 2013) |
| "Type 2 diabetes mellitus is characterized by insulin resistance in peripheral tissues and relative impairment in insulin secretion from pancreatic beta cell." | ( Shimomura, I; Yasuda, T, 2013) |
| "Type 2 diabetes mellitus is the most common endocrine disease all over the world, while existing therapies can only ameliorate hyperglycemia or temporarily improve the response to insulin in target tissues, they cannot retard or improve the progressive β-cell dysfunction persistently." | ( Gao, H; Hu, J; Sun, R; Wang, F; Wang, L; Wang, Y; Wang, Z; Yan, S; Yu, X; Zhao, W, 2014) |
| "Type 2 diabetes mellitus is a pandemic, with millions of new diagnoses made each year." | ( Davidson, JA; Grimm, M; Nikkel, C, 2013) |
| "Type 2 diabetes mellitus is an increasingly common threat to the health of elderly Americans." | ( Marcy, TR; Zhao, Q, 2013) |
| "Type 2 diabetes mellitus is characterized by prolonged hyperinsulinemia, insulin resistance, and progressive hyperglycemia." | ( Berg, RL; Doi, SA; Engel, JM; Glurich, I; Onitilo, AA; Stankowski, RV; Williams, GM, 2014) |
| "Type 2 diabetes mellitus is increasing dramatically in sub-Saharan Africa, and genetic predisposition is likely involved in that." | ( Bedu-Addo, G; Danquah, I; Frank, LK; Mockenhaupt, FP; Othmer, T; Schulze, MB, 2013) |
| "Type 2 diabetes mellitus is a complex and progressive disease that is showing an apparently unstoppable increase worldwide." | ( Capuano, A; Esposito, K; Giugliano, D; Maiorino, MI; Rossi, F; Sportiello, L, 2013) |
| "Type 2 diabetes mellitus is a troubling chronic disease and diabetic nephropathy is one of the most important complications of diabetes mellitus." | ( Ardalan, MR; Baradaran, A; Mardani, S; Momeni, A; Nasri, H; Rafieian-Kopaei, M, 2013) |
| "Type 2 diabetes mellitus is a major risk factor for melioidosis, which is caused by Burkholderia pseudomallei." | ( Ato, M; Bancroft, GJ; Kewcharoenwong, C; Lertmemongkolchai, G; Rinchai, D; Suwannasaen, D; Utispan, K, 2013) |
| "Type 2 diabetes mellitus is increasingly diagnosed in obese children and adolescents." | ( Narasimhan, S; Weinstock, RS, 2014) |
| "Type 2 Diabetes Mellitus is most common form of diabetes." | ( Garg, K; Kumar, S; Tripathi, CD, 2013) |
| "Individuals with type 2 diabetes mellitus are at increased risk of developing atherosclerosis." | ( Greenberg, AS; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Obin, MS; Ronxhi, J; Spartano, NL, 2014) |
| "Type 2 diabetes mellitus is a progressive and heterogeneous disease." | ( de Kalbermatten, B; Jaafar, J; Jornayvaz, FR; Philippe, J, 2014) |
| "Type 2 diabetes mellitus is associated with a poor quality of life and considerable health-care costs and can be difficult to control." | ( Derosa, G; Maffioli, P, 2014) |
| "Type 2 diabetes mellitus is highly prevalent among the elderly." | ( Ferriolli, E; Marchesi, JC; Pessanha, FP, 2014) |
| "Type 2 diabetes mellitus is affecting more than 382 million people worldwide." | ( Beales, PL; Berggren, PO; Christou-Savina, S; Gerdes, JM; Karlsson-Edlund, P; Leibiger, B; Leibiger, IB; Moede, T; Moruzzi, N; Östenson, CG; Xiong, Y, 2014) |
| "Type 2 diabetes mellitus is one of the most frequent causes of death in Mexico, characterized by chronic hyperglycemia." | ( Allen, K; Flores-Fernandez, JM; Lazcano-Díaz, E; Owolabi, MS; Padilla-Camberos, E; Villanueva-Rodríguez, S, 2014) |
| "Type 2 diabetes mellitus is a progressive disease that requires pharmacologic treatment to prevent microvascular and macrovascular complications." | ( Gurgle, H; McAdam-Marx, C; Schauerhamer, MB, 2015) |
| "Type 2 diabetes mellitus is the predominant form of diabetes." | ( Chang, SL; Lee, YC; Liao, HY; Lin, JG; Sun, MF, 2015) |
| "Type 2 diabetes mellitus is a vast growing progressive disease that almost affects one person among every twelve globally." | ( Abdulla, MM; Badrey, MG; Eldebss, TM; Gomha, SM; Mayhoub, AS, 2015) |
| "Type 2 diabetes mellitus is characterised by persistent thromboxane (TX)-dependent platelet activation, regardless of disease duration." | ( Davì, G; Pignatelli, P; Santilli, F; Violi, F, 2015) |
| "Type 2 diabetes mellitus is an important risk factor in the development of coronary artery disease (CAD) and is often associated with severe disease." | ( Bhat, NM; Kamath, PK; Mahabala, C; Manjrekar, PA; Pai, ND; Srinivasan, MP, 2015) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder that has become the fourth leading cause of death in the developed countries." | ( Lee, CY, 2016) |
| "Patients with type 2 diabetes mellitus are known to have an increased risk of colorectal neoplasia." | ( Abe, Y; Fujiwara, K; Higuchi, K; Iguchi, M; Inoue, T; Kakimoto, K; Kawakami, K; Nouda, S; Okada, T; Takeuchi, T; Yorifuji, N, 2016) |
| "Type 2 diabetes mellitus is a complex metabolic disease, and cardiovascular disease is a leading complication of diabetes." | ( Antunes, M; Burgeiro, A; Carvalho, E; Carvalho, RA; Cherian, S; Espinoza, D; Fuhrmann, A; Jarak, I; Loureiro, M; Patrício, M, 2016) |
| "Patients with type 2 diabetes mellitus are at risk for accelerated cognitive decline and dementia." | ( Biessels, GJ; Groeneveld, ON; Kappelle, LJ, 2016) |
| "Obesity and type 2 diabetes mellitus are increasing worldwide, reaching pandemic proportions." | ( Celik, A; Celik, BO; Dixon, JB; Gupta, A; Karaca, FC; Pouwels, S; Santoro, S; Ugale, S, 2016) |
| "Because type 2 diabetes mellitus is associated strongly with an increased risk of cardiovascular diseases, the number of patients with diabetes with chronic heart failure is increasing steadily." | ( Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A, 2016) |
| "Type 2 diabetes mellitus is the result of impaired systemic control of glucose homeostasis, in part through the dysregulation of the hormone glucagon." | ( Birnbaum, MJ; Miller, RA, 2016) |
| "Type 2 diabetes mellitus is associated with regulation of several miRNAs in skeletal muscle." | ( Armitage, JA; Heywood, SE; Kingwell, BA; Latouche, C; Natoli, A; Reddy-Luthmoodoo, M, 2016) |
| "Obesity and type 2 diabetes mellitus are risk factors for developing Alzheimer disease." | ( Gupta, D; Jones, AM; Jones, KP; Pratley, RE; Smith, J; Tharp, WG, 2016) |
| "Type 2 diabetes mellitus is characterized by chronic hyperglycemia and associated with oxidative stress resulting from accumulation of free radicals in body's tissues, which especially affects beta cells in pancreas and is an important factor in the development of diabetes and its complications." | ( Askar, T; Mansour, AA; Mergani, A; Mohammed, MA; Mustafa, AM; Saleh, OM; Zahran, RN, 2016) |
| "Type 2 diabetes mellitus is often complicated by osteoporosis, a process which may involve osteoblast autophagy." | ( Liu, F; Liu, JH; Meng, HZ; Shi, PX; Sun, GH; Yang, B; Yang, MW; Yang, RF; Zhang, WL, 2016) |
| "Type 2 diabetes mellitus is a progressive disease associated with significant morbidity and mortality." | ( Anderson, R; Hayes, J; Stephens, JW, 2016) |
| "Type 2 diabetes mellitus is characterized by the dysregulation of glucose homeostasis, resulting in hyperglycaemia." | ( Puigserver, P; Rines, AK; Sharabi, K; Tavares, CD, 2016) |
| "Type 2 diabetes mellitus is a complex metabolic disease and its pathogenesis involves abnormalities in both peripheral insulin action and insulin secretion." | ( Álvarez, C; Beneit, N; Benito, M; Chambon, P; Di Scala, M; Diaz-Castroverde, S; Escribano, O; Fernández, S; Fernández-Millán, E; García-Bravo, M; García-Gómez, G; Gómez-Hernández, A; González-Aseguinolaza, G; González-Rodríguez, Á; Perdomo, L, 2016) |
| "Type 2 diabetes mellitus is associated with accelerated cognitive decline." | ( Backes, WH; Edden, RAE; Hofman, PAM; Jansen, JFA; Puts, NAJ; Schram, MT; Stehouwer, CDA; van Boxtel, MPJ; van Bussel, FCG; Wildberger, JE, 2016) |
| "Type 2 diabetes mellitus is closely associated with adipogenesis and their factors." | ( Arasu, MV; Choi, KC; Ilavenil, S; Kim, da H; Lee, JS; Roh, SG; Srigopalram, S; Vijayakumar, M, 2016) |
| "Type 2 diabetes mellitus is associated strongly with an increased risk of micro- and macro-vascular complications, leading to impaired quality of life and shortened life expectancy." | ( Eguchi, K; Higashi, Y; Inoue, T; Ishizu, T; Kadokami, T; Kario, K; Kitakaze, M; Kodera, S; Maemura, K; Matsuhisa, M; Murohara, T; Nanasato, M; Nishio, Y; Node, K; Ohishi, M; Oyama, J; Sata, M; Sato, Y; Shimabukuro, M; Suzuki, M; Taguchi, I; Tanaka, A; Teragawa, H; Tomiyama, H; Ueda, S; Yamada, H, 2016) |
| "Type 2 diabetes mellitus is chronic metabolic disorder." | ( Bhadada, SK; Malik, A; Morya, RK; Rana, S; Sachdeva, N; Sharma, G, 2016) |
| "Type 2 diabetes mellitus is prevalent especially in Gulf countries and poses serious long-term risks to patients." | ( Al-Saber, F; Aldosari, W; Alselaiti, M; Darwish, A; Harb, G; Kaladari, A; Khalfan, H; Khan, G; Koda, A; Kudo, S; Nakajima, M; Rehani, R; Tanaka, T, 2016) |
| "Type 2 diabetes mellitus is characterized by insulin resistance in various insulin target tissues, such as the liver, adipose tissue, and skeletal muscle, and insufficient insulin secretion from pancreatic β-cells." | ( Kaku, K; Kaneto, H; Kimura, T; Matsuoka, TA; Obata, A; Okauchi, S; Shimo, N; Shimoda, M, 2017) |
| "Type 2 diabetes mellitus is a polygenic disease with a variable phenotype." | ( Sharma, A; Vella, A, 2017) |
| "Type 2 diabetes mellitus is associated with a progressive decline in insulinproducing pancreatic β-cells, an increase in hepatic glucose production, and a decrease in insulin sensitivity." | ( Holst, JJ; McGill, MA, 2012) |
| "Type 2 diabetes mellitus is a pandemic associated with disturbance in haemostasis that could contribute to the development of diabetic vascular disease and accelerated atherosclerosis." | ( Bester, J; Pretorius, E; Soma, P; Swanepoel, AC, 2017) |
| "Type 2 diabetes mellitus is a progressive disease with multiple underlying pathophysiologic defects." | ( Dey, J, 2017) |
| "Expert commentary: Type 2 diabetes mellitus is an epidemic disease and represents a challenge for all health care systems." | ( Acurcio, FA; De Oliveira, GL; Godman, B; Guerra Júnior, AA, 2017) |
| "Type 2 diabetes mellitus is a disease with no cure and chronic disease that results in major morbidity and mortality." | ( Abougalambou, AS; Abougalambou, SSI; Ahmed, NO, 2017) |
| "Type 2 Diabetes Mellitus is a very well known metabolic disorder that has reached epidemic proportions worldwide." | ( Achalli, S; Babu, S; Bhat, M; Kumari, S; Madi, M; Madiyal, A; Shetty, S, 2016) |
| "Type 2 diabetes mellitus is the most common form of diabetes that occurs in both human and nonhuman primates." | ( Gash, DM; Quintero, JE; Yue, F; Zhang, G; Zhang, Z, 2017) |
| "Type 2 diabetes mellitus is a worldwide epidemic and its atherosclerotic complications determine the high morbidity and mortality of diabetic patients." | ( Deleanu, M; Niculescu, LS; Sanda, GM; Sima, AV; Stancu, CS; Toma, L, 2017) |
| "Type 2 diabetes mellitus is characterized by relative insulin deficiency and insulin resistance." | ( Anzaldi, L; Fesseha, B; Galiatsatos, P; Kim, HN; Sidhaye, A; Tsao, A, 2018) |
| "Type 2 diabetes mellitus is associated with increased fracture risk, and recent studies show crosstalk between bone and glucose metabolism." | ( Grimnes, G; Jorde, R; Larsen, AU, 2018) |
| "Type 2 diabetes mellitus is a common disease, affecting up to 13." | ( Azinheira, J; Capitão, RM; Sequeira Duarte, J; Tavares Bello, C; Vasconcelos, C, 2017) |
| "Type 2 diabetes mellitus is associated with cognitive dysfunction and an increased risk of dementia." | ( Biessels, GJ; Espeland, MA; Janssen, J; Johansen, OE; Mattheus, M; van den Berg, E; Zinman, B, 2018) |
| "Type 2 diabetes mellitus is a polygenic metabolic disorder resulting from oxidative stress, the root cause of insulin resistance, β-cell dysfunction and impaired glucose tolerance." | ( Chen, Z; Hu, Z; Liu, D; Liu, L; Song, Z; Wang, Y, 2018) |
| "Type 2 diabetes mellitus is now a worldwide health problem with increasing prevalence." | ( Liu, DM; Liu, JM; Mosialou, I, 2018) |
| "Type 2 diabetes mellitus is characterized by peripheral insulin resistance and low-grade systemic inflammation." | ( Barden, A; Beilin, L; Hodgson, JM; Mas, E; Mori, TA; Phillips, M; Puddey, I; Shinde, S, 2018) |
| "Type 2 diabetes mellitus is a worldwide health problem." | ( Czyrski, A; Hermann, T; Resztak, M, 2018) |
| "Type 2 diabetes mellitus is a common and severe chronic metabolic disease, which confers increased risk of cardiovascular disease and mortality." | ( Christensen, MB; Sørensen, AM, 2018) |
| "Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney disease." | ( Alexander, JH; Baanstra, D; Cooper, ME; George, JT; Johansen, OE; Kahn, SE; Marx, N; McGuire, DK; Meinicke, T; Perkovic, V; Pfarr, E; Rosenstock, J; Schnaidt, S; Toto, RD; von Eynatten, M; Wanner, C; Zinman, B, 2019) |
| "Type 2 diabetes mellitus is among the most common diseases seen in primary care practices and can lead to significant complications." | ( Holley, A; Martinez, LC; Sherling, D, 2019) |
| "Type 2 diabetes mellitus is a major risk factor for cardiovascular disease." | ( Al-Salameh, A; Becquemont, L; Bucher, S; Chanson, P; Ringa, V, 2019) |
| "Patients with type 2 diabetes mellitus are at an increased risk of adverse cardiovascular events compared to those without diabetes." | ( Kolluri, N; Lerman, A; Lerman, LO; Sara, JD; Taher, R; Vella, A, 2019) |
| "Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available." | ( Agarwal, R; Bakris, G; Bompoint, S; Brenner, BM; Bull, S; Cannon, CP; Capuano, G; Charytan, DM; Chu, PL; de Zeeuw, D; Edwards, R; Greene, T; Heerspink, HJL; Jardine, MJ; Levin, A; Mahaffey, KW; Meininger, G; Neal, B; Perkovic, V; Pollock, C; Wheeler, DC; Yavin, Y; Zhang, H; Zinman, B, 2019) |
| "Type 2 diabetes mellitus is a complex metabolic disorder requiring polypharmacology approaches for effective treatment." | ( Babkov, DA; Babkova, VA; Borisov, AV; Borodkin, GS; Brigadirova, AA; Kolodina, AA; Litvinov, RA; Morkovnik, AS; Sochnev, VS; Sokolova, EV; Spasov, AA; Zhukowskaya, ON, 2019) |
| "Type 2 diabetes mellitus is a major health concern worldwide; however, the molecular mechanism underlying its development is poorly understood." | ( Cooper, GJS; Liu, H; McCann, MJ; Nie, T; Vazhoor Amarsingh, G; Zhang, S, 2019) |
| "The prevalence of type 2 diabetes mellitus is expected to rise in the frail elderly population, which will have significant consequences for the health economy." | ( Muraleedharan, V; Rabindranathnambi, A; Sathyanarayanan, A, 2019) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder characterized by elevated blood glucose and/or high serum free fatty acids." | ( Hua, Q; Kong, X; Li, XY; Liu, CX; Lv, K; Ma, MZ; Su, Q; Wang, GD; Yang, H; Yao, XM; Zhang, HM, 2019) |
| "Type 2 diabetes mellitus is a major risk factor for developing cardiovascular disease, and many patients with diabetes have prevalent cardiovascular complications." | ( Ceriello, A; Ferrini, M; La Sala, L; Marx, N; Prattichizzo, F; Rydén, L; Valensi, P, 2019) |
| "Type 2 diabetes mellitus is an important public health problem, with a significant impact on cardiovascular morbidity and mortality and an important risk factor for chronic kidney disease." | ( Foresto, RD; Gonzalez, DE; Ribeiro, AB, 2020) |
| "Type 2 diabetes mellitus is often companied with osteoporosis, a process which involves osteoclast activation." | ( Gong, Y; Lei, X; Liu, H; Song, Z; Xie, J; Yang, M; Zhou, L, 2020) |
| "Obesity and type 2 diabetes mellitus are global emergencies and long noncoding RNAs (lncRNAs) are regulatory transcripts with elusive functions in metabolism." | ( Awazawa, M; Büning, H; Cao, H; Dhaouadi, I; Dieterich, C; Edwards, PA; Fernandez-Rebollo, E; Frommolt, P; Hansmeier, NR; Heeren, J; Heine, M; Jesus, DF; Khani, S; Kiefer, CA; Klemm, P; Knippschild, U; Kornfeld, JW; Kulkarni, RN; Larsen, BD; Lee, RG; Link, JC; Loureiro, R; Meola, N; Oliverio, M; Pradas-Juni, M; Scheja, L; Schmidt, E; Schwarzer, R; Topel, H; Tröder, SE; Ulitsky, I; Vallim, TQA; Yamamoto, M; Yang, L; Zevnik, B, 2020) |
| "Type 2 diabetes mellitus is associated with an increased risk of heart failure." | ( Bondugulapati, LNR; Morgan, H; Nana, M, 2021) |
| "Type 2 diabetes mellitus is associated with pNET metastasis and not an independent risk factor for poor prognosis in pNETs." | ( Cheng, H; Fan, K; Fan, Z; Gong, Y; Huang, Q; Jin, K; Liu, C; Luo, G; Ni, Q; Yang, C; Yu, X, 2020) |
| "Objectives Type 2 Diabetes mellitus is a progressive metabolic disease characterized by relative insulin insufficiency and insulin resistance resulting in hyperglycemia." | ( Abrahams-October, Z; Adeniyi, OV; Benjeddou, M; Johnson, R; Masilela, CM; Ongole, JJ; Pearce, B; Xhakaza, L, 2020) |
| "Type 2 Diabetes mellitus is associated with aging and shortened telomere length." | ( Abdolahi, A; Block, RC; Brenna, JT; Godugu, K; Holub, A; Mousa, S; Tu, XM, 2020) |
| "Type 2 diabetes mellitus is a chronic disease that is characterized by hyperglycemia, insulin resistance, and dysfunctional insulin secretion." | ( Ho, HJ; Komai, M; Shirakawa, H, 2020) |
| "Type 2 diabetes mellitus is a heterogeneous disease." | ( Birkenfeld, AL; Fritsche, A; Gallwitz, B; Häring, HU; Heni, M; Kellerer, M; Peter, A; Wagner, R, 2022) |
| "Type 2 diabetes mellitus is a heterogeneous disease." | ( Birkenfeld, AL; Fritsche, A; Gallwitz, B; Häring, HU; Heni, M; Kellerer, M; Peter, A; Wagner, R, 2022) |
| "The incidence of type 2 diabetes mellitus is increasing worldwide and nowadays T2D already became a global epidemic." | ( Danilova, MM; Glotov, AS; Mikhailova, AA; Nasykhova, YA; Tonyan, ZN, 2020) |
| "Obesity and type 2 diabetes mellitus are the most extended current chronic diseases and also Alzheimer pathology which is a progressive degenerative neurological disorder." | ( Cano-Lamadrid, M; Carbonell-Barrachina, ÁA; Hernández, F; Lech, K; Nowicka, P; Tkacz, K; Turkiewicz, IP; Wojdyło, A, 2021) |
| "Type 2 diabetes mellitus is closely related to nonalcoholic fatty liver disease(NAFLD)." | ( Guo, W; Lin, L; Tian, W; Xu, X, 2020) |
| "Type 2 diabetes mellitus is responsible for high mortality and morbidity globally and in India." | ( Babu, GR; Gudlavalleti, AG; Lewis, MG; Murthy, GVS; Schaper, NC; van Schayck, OCP, 2020) |
| "Type 2 diabetes mellitus is characterized by insulin resistance and elevated blood glucose levels." | ( Handschuh, P; Lanzenberger, R; Noe, CA; Noe, CR; Noe-Letschnig, M; Soucek-Noe, D; Wolfslehner, L, 2020) |
| "Type 2 diabetes mellitus is strongly associated with cardiac mitochondrial dysfunction, which is one of the main reasons for cardiovascular diseases." | ( Gopala, S; Jayakumari, NR; Parambil, ST; Rajendran, RS; Reghuvaran, AC; Sivasailam, A; Sreelatha, HV, 2021) |
| "Aging, obesity and type 2 diabetes mellitus are associated with perfusion abnormalities leading to cognitive impairment, neurodegeneration and future development of dementia." | ( Barna, S; Budai, Á; Esze, R; Garai, I; Káplár, M; Képes, Z; Nagy, F; Somodi, S; Varga, J, 2021) |
| "Type 2 diabetes mellitus is a complicated metabolic disorder with no definite treatment." | ( Akhtar, B; Hassan, SU; Malik, M; Muhammad, F; Saeed, M; Sharif, A, 2022) |
| "Type 2 diabetes mellitus is a severe public health issue worldwide." | ( Alfonsetti, M; Allegretti, M; Brandolini, L; Castelli, V; Cimini, A; Cocchiaro, P; d'Angelo, M; Giorgio, C; Lombardi, F, 2021) |
| "Type 2 diabetes mellitus is a chronic metabolic disorder that tends to disarray various metabolic pathways." | ( Jayachandran, M; Li, X; Xu, B, 2021) |
| "Type 2 Diabetes mellitus is a chronic disease considered one of the most severe global health emergencies." | ( Cardullo, N; Floresta, G; Muccilli, V; Rescifina, A; Tringali, C, 2021) |
| "Type 2 diabetes mellitus is a complex metabolic disorder associated with obesity, glucose intolerance and insulin resistance." | ( Bo, P; Fang, P; Han, L; Han, S; Huang, Y; Wang, M; Yu, M; Zhang, Z, 2022) |
| "Type 2 diabetes mellitus is one of the most common and life-threatening diseases found across the globe." | ( Chellappan, DK; Dua, K; Dureja, H; Gulati, M; Gupta, G; Gupta, PK; Gupta, S; Jha, NK; Jha, SK; Khursheed, R; Kumar, B; Pandey, NK; Prasher, P; Sharma, A; Singh, SK; Vishwas, S, 2022) |
| "Type 2 diabetes mellitus is known to be a risk factor for Alzheimer’s disease (AD), but the underlying mechanisms remain unclear." | ( Nomura, S; Shigemori, K; Takeda, S; Tomiyama, T; Umeda, T, 2022) |
| "Type 2 diabetes mellitus is one of the most globally common chronic diseases." | ( Abuzaid, O; Al-Sheikh, R; Albannawi, M; Alhajjmohammed, D; Alkubaish, Z; Althani, R; Altheeb, L; Altuwajiry, H; Ayoub, H; Khattab, R; Mutwalli, H; Purayidathil, T, 2023) |
| "The incidence of type 2 diabetes mellitus is increasing among youths." | ( Arslanian, SA; Barrientos-Pérez, M; Bismuth, E; Boucher-Berry, C; Chao, LC; Cho, JI; Cox, D; Dib, S; Hannon, T; Zeitler, P, 2022) |
| "Type 2 diabetes mellitus is a chronic disease associated with obesity and dysregulated human feeding behavior." | ( Allbritton, NL; Sims, CE; Villegas-Novoa, C; Wang, Y, 2022) |
| "Type 2 diabetes mellitus is a high-risk factor for acute cardiovascular events." | ( Shao, G, 2022) |
| "Type 2 diabetes mellitus is a global epidemic disease, which leads to a severe complication named increased bone fracture risk." | ( Gong, H; Hu, X; Jia, S; Li, J; Wu, X, 2022) |
| "Type 2 diabetes mellitus is a chronic disease most often characterized by increased glucose levels." | ( Ashchi, A; Berner, J; Goldfaden, R; Gore, A; Huston, J; Langley, L; Schaffner, H; Sheikh-Ali, M; Skrable, B; Sutton, D, 2022) |
| "Obesity and Type 2 diabetes mellitus are growing health problems all over the world." | ( Keskin, L; Yaprak, B, 2022) |
| "Type 2 diabetes mellitus is considered to be a substantial socioeconomic burden worldwide on both patients and governments." | ( Abdelwahab, MF; AlYahya, KA; Ibrahim, HM; Khalil, HE; Mohamed, AA; Radwan, AS; Waz, S, 2022) |
| "Type 2 diabetes mellitus is a metabolic disorder resulting from impaired insulin secretion and resistance." | ( Chhabria, S; Mathur, S; Mishra, P; Paital, B; Sahoo, DK; Vadakan, S, 2022) |
| "Type 2 diabetes mellitus is a metabolic disorder resulting from impaired insulin secretion and resistance." | ( Chhabria, S; Mathur, S; Mishra, P; Paital, B; Sahoo, DK; Vadakan, S, 2022) |
| "T2DM (Type 2 diabetes mellitus) is considered a disease that affects old age group." | ( Eid, Y; Elhalawany, S; Elhefnawy, M; Halawa, M; Hegab, A; Hendawy, L, 2022) |
| "Type 2 diabetes mellitus is associated with an increased risk of dementia, potentially through multifactorial pathologies, including neuroinflammation." | ( Ihara, M; Iwasa, M; Iwashita, K; Kato, H; Kato, S; Kawamoto, A; Nishimura, H; Saito, S; Satoh-Asahara, N; Suganami, T; Tanaka, M; Yamakage, H, 2023) |
| "Type 2 diabetes mellitus is a globally prevalent chronic disease characterised by hyperglycaemia and oxidative stress." | ( Acevedo, F; Folch, C; Galarce-Bustos, O; Obregón, C; Vallejos-Almirall, A, 2023) |
| "Type 2 diabetes mellitus is characterized by hyperglycemia and insulin resistance." | ( Ahmed Rasheed, R; Asim, M; Aysha Iftikhar, Z; Chen, TW; Farooq, M; Musaed Almutairi, S; Mushtaq, U; Ubaid, M; Ul Ain, I, 2023) |
| "Type 2 diabetes mellitus is a chronic metabolic disease with no cure." | ( Krause-Hauch, M; Lui, A; Patel, NA; Patel, RS; Sparks, RP, 2023) |